Nanosuspension-Based Drug Delivery Systems for Topical Applications

Mohamed Aldeeb,Gofarana Wilar,Cecep Suhandi,Khaled Elamin,Nasrul Wathoni
DOI: https://doi.org/10.2147/ijn.s447429
IF: 7.033
2024-01-26
International Journal of Nanomedicine
Abstract:Mohamed Mahmud E Aldeeb, 1, 2, &ast Gofarana Wilar, 3, &ast Cecep Suhandi, 1, &ast Khaled M Elamin, 4, &ast Nasrul Wathoni 1, &ast 1 Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, 45363, Indonesia; 2 Department of Pharmaceutics, Faculty of Pharmacy, Elmergib University, Alkhoms, 40414, Libya; 3 Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, 45363, Indonesia; 4 Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, 862-0973, Japan &astThese authors contributed equally to this work Correspondence: Nasrul Wathoni, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, 45363, Indonesia, Tel +62-22-842-888-888, Email Nanosuspensions have garnered recent attention as a promising strategy for mitigating the bioavailability challenges of hydrophobic drugs, particularly those characterized by poor solubility in both aqueous and organic environments. Addressing solubility issues associated with poorly water-soluble drugs has largely resolved the need to enhance drug absorption and bioavailability. As mucosal formulations and topical administration progress in the future, nanosuspension drug delivery, straightforward formulation techniques, and versatile applications will continue to be subjects of interest. Nanosuspensions have undergone extensive scrutiny in preparation for topical applications, encompassing ocular, pulmonary, and dermal usage. Among the numerous methods aimed at improving cutaneous application, nanocrystals represent a relatively recent yet profoundly intriguing approach. Despite the increasing availability of various nanosuspension products, primarily designed for oral administration, only a limited number of studies have explored skin permeability and drug accumulation in the context of nanosuspensions. Nevertheless, the scant published research unequivocally underscores the potential of this approach for enhancing cutaneous bioavailability, particularly for active ingredients with low to medium solubility. Nanocrystals exhibit increased skin adhesiveness in addition to heightened saturation solubility and dissolution rate, thereby augmenting cutaneous distribution. The article provides a comprehensive overview of nanosuspensions for topical application. The methodology employed is robust, with a well-defined experimental design; however, the limited sample size raises concerns about the generalizability of the findings. While the results demonstrate promising outcomes in terms of enhanced drug delivery, the discussion falls short of addressing certain limitations. Additionally, the references largely focus on recent studies, but a more diverse inclusion of historical perspectives could offer a more holistic view of the subject. Keywords: nanosuspension, nanotechnology, topical, dermal Over the past two decades, there has been a notable emergence of cutting-edge advancements in the realm of pharmaceutical research and development. The automation of the drug discovery process, facilitated by technologies such as high-throughput screening, combinatorial chemistry, and computer-aided drug design, has resulted in the generation of a substantial array of highly effective drug candidates. 1 Regrettably, a considerable proportion of these promising medications grapple with the challenge of low water solubility, with approximately 40% of drugs in the developmental pipeline encountering solubility issues. 2,3 High-throughput screening techniques have contributed to the identification of an increasing number of drugs exhibiting limited water solubility. The constrained solubility of these compounds poses a significant impediment during the initial phases of screening for pharmacological activity, as well as throughout the formulation development and clinical testing processes. 4 Preparing one of these substances for preclinical investigations and pharmacological activity assessments is a prerequisite well in advance of their commercialization. 5 Consequently, it becomes evident that the adoption of innovative technical strategies is imperative to augment the bioavailability of drugs characterized by low solubility. The predominant challenge faced by the pharmaceutical industry resides in the development of novel formulation procedures and drug delivery technologies tailored to effectively address the solubility limitations associated with therapeutic candidates. These concerns frequently intersect with issues pertaining to low oral bioavailability. 6–8 To atta -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology
What problem does this paper attempt to address?